Treat Stroke to Target

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

2873 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-15

Study Completion Date

2019-05-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is the evaluation of two usual care strategies after stroke or TIA : achieved target LDL-C of 100 mg/dL (+/-10 mg/dL) or less than 70 mg/dL. Investigators will use the statin and titrate the dosage to achieve the target assigned by randomization in monotherapy or in combination with ezetimibe or other drugs.

The primary end-point is the occurrence of recurrent non fatal stroke, non fatal MI, and vascular death in each group.

3760 patients will be recruited and followed for eight and a half years maximum.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Short-term Intensive Statin Therapy on Lipid Levels

NCT07344610

Ischemic Stroke

RECRUITING

Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis

NCT07307989

Ischemic Stroke Hypercholesteremia

RECRUITING PHASE2

Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis

NCT02458755

Stroke Intracranial Atherosclerosis

UNKNOWN PHASE4

Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke

NCT00147602

Cardiovascular Disease

COMPLETED PHASE4

Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting

NCT01255852

CVD

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this study is the evaluation of two usual care strategies after stroke or TIA : achieved target LDL-C of 100 mg/dL (+/-10 mg/dL) or less than 70 mg/dL. Investigators will use the statin and titrate the dosage to achieve the target assigned by randomization in monotherapy or in combination with ezetimibe or other drugs.

Inclusion criteria:

* Recent (less than 3 months) ischemic stroke As soon as possible after the event, once the neurologic deficit is stabilized (investigator judgment). These ischemic strokes include TIA with ischemic lesion documented by CT or MRI.
* Or recent TIA (less than 15 days) without documentation of ischemic lesion on CT/MR imaging. Must be limb weakness or aphasia lasting more than 10 min.
* And documented atherosclerotic stenosis in carotid artery (investigator judgment) (based on the results of Duplex echography, CTA, MRA or X ray- angiography), Or in the aortic arch (investigator judgment) (based on TEE or CTA), Or in other brain artery: vertebral, basilar or other intracranial artery (based on CTA, MRA, XRA), Or in coronary arteries (past history of acute coronary syndrome, coronary revascularization or positive coronary angiography)
* And statin treatment is indicated, following ANSM guidelines (French drug agency), age \>18 years, rankin score ≤ 4, patient or a legal representative signs consent, patient is affiliated to social security system

Exclusion criteria :

* Ischemic stroke/TIA du to arterial dissection (investigator judgment)
* Cardiac source of embolism (e.g., mitral stenosis, endomyocardial fibrosis) without documented atherosclerotic stenosis : a patient with atrial fibrillation or a past history of recent myocardial infarction or calcified aortic stenosis can be randomized if he otherwise fulfils inclusion criteria
* Symptomatic hemorrhagic stroke : Presence of microbleeds on gradient echo imaging (T2\*) is not an exclusion criteria. Hemorrhagic transformation of an ischemic stroke is not an exclusion criteria
* Uncontrolled hypertension (investigator judgment)
* LDL-C \<100 mg/dL or patients for whom treatment intensification is impossible
* F/U impossible or bad observance anticipated.
* Co-morbid condition that may interfere with the F/U or with the evaluation of primary endpoint
* Participation to another clinical trial

The primary end-point is:

Recurrent ischemic stroke or stroke of undetermined origin, myocardial infarction, urgent coronary or carotid revascularization following new symptoms requiring hospitalization, and vascular death.

Secondary endpoints:

* Recurrent nonfatal ischemic stroke
* Nonfatal myocardial infarction
* Recurrent ischemic stroke, fatal or non
* Recurrent ischemic stroke or TIA
* Intracranial hemorrhage (intracerebral hemorrhage, subarachnoid hemorrhage, subdural hematoma)
* All stroke (ischemic or hemorrhagic)
* Any major coronary events (including fatal and nonfatal myocardial infarction)
* Any coronary heart disease end-point (myocardial infarction, hospitalization for acute corornary symptoms, coronary revascularization procedure)
* Any revascularisation procedure (coronary, carotid, or peripheral artery))
* Carotid artery revascularization procedure (urgent following new symptoms or elective)
* Vascular death (ischemic stroke or undetermined stroke, fatal myocardial infarction, other vascular deaths, sudden death, death of undetermined cause, i.e., without other cause documented such as cancer, infection, accident, suicide, etc…)
* All causes deaths
* Primary endpoint plus intracranial hemorrhage
* New onset diabetes

Hypothesis :

* Follow-up of three years
* Risk of primary end-point in the control group (Target LDL \<100 mg/dL) : 4% per year (12 % at 36 months)
* 5% Alpha, 80% power, total number of subject is :
* 3068 patients with a RRR 25%
* 20% drop-out: 3760 patients (385 primary EP)

Study specifications Follow-up : eight and a half years Follow-up visit : every 6 months Number of centers (French Stroke Units, under the auspice of the French Neurovascular Society) : 60-100

Ancillary study As an ancillary study, 800 patients (400 in each arm in 4 centers) will participate in the TST-PLUS (Plaque Ultrasound Study), in which they will have three ultrasound examination (baseline, 1 year and 3 years) and baseline blood sampling. The primary endpoint of this substudy will be the rate of occurrence of new carotid plaque, with the hypothesis that Rate of plaque occurrence in the \<100 mg/dL group will be 25% after 3 years (45% in EVA when atherosclerosis was present at baseline) RRR of plaque of 25% in the \<70 mg/dL group Alpha 5%, power 80%

As an ancillary study, 1000 patients will participate in the TST-PGS (Pharmacogenetics) Study, in which they will have 1 blood sampling either at baseline or during one of the follow-up visits of TST. The aim of this study is to show that the benefit (risk of ischemic stroke, myocardial infarction, and vascular death) observed with a strategy of LDL-C \<0.7 g / l compared to a strategy of LDL-C to 1 ± 0.1 g / l is higher in carriers of polymorphism 719Arg of the gene KIF-6 than non-carriers of this polymorphism.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke Transient Ischemic Attack Atherosclerotic Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LDL-C to100 mg/dL (+/-10 mg/dL)

Target : 100 mg/dL (+/-10 mg/dL):

Patients recruited in this arm will receive statin +/-other lipid lowering therapy in order to reach a LDL-C concentration of 100 mg/dL(+/-10 mg/dL).

Group Type OTHER

Target : 100 mg/dL (+/-10 mg/dL)

Intervention Type PROCEDURE

Statin +/- other lipid lowering therapy during 3 years, Target : LDL-C =100 mg/dL (+/-10 mg/dL), recording recurrent non fatal stroke, non fatal MI, and vascular death and others endpoints such as new onset diabetes, hemorrhagic strokes.

LDL-C < 70 mg/dL

70 mg/dL: Patients recruited in this arm will receive statin +/-other lipid lowering therapy in order to reach a LDL-C concentration of less than 70 mg/dL.

Group Type OTHER

70 mg/dL

Intervention Type PROCEDURE

Statin +/-lipid lowering therapy during eight and a half years maximum, Target : LDL-C concentration of less than 70 mg/dL, recording recurrent of non fatal stroke, non fatal IM, and vascular death and others endpoints such as: new onset diabetes, hemorrhagic strokes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Target : 100 mg/dL (+/-10 mg/dL)

Statin +/- other lipid lowering therapy during 3 years, Target : LDL-C =100 mg/dL (+/-10 mg/dL), recording recurrent non fatal stroke, non fatal MI, and vascular death and others endpoints such as new onset diabetes, hemorrhagic strokes.

Intervention Type PROCEDURE

70 mg/dL

Statin +/-lipid lowering therapy during eight and a half years maximum, Target : LDL-C concentration of less than 70 mg/dL, recording recurrent of non fatal stroke, non fatal IM, and vascular death and others endpoints such as: new onset diabetes, hemorrhagic strokes.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

treat to target treat to target

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Recent (less than 3 months) ischemic stroke
* As soon as possible after the event, once the neurologic deficit is stabilized (investigator judgment)
* These ischemic strokes include TIA with ischemic lesion documented by CT or MRI

• Or recent TIA (less than 15 days)
* without documentation of ischemic lesion on CT/MR imaging
* Must be limb weakness or aphasia lasting more than 10 min

• And documented atherosclerotic stenosis
* In carotid artery (investigator judgment) (based on the results of Duplex echography, CTA, MRA or X ray- angiography)
* Or in the aortic arch (investigator judgment) (based on TEE or CTA)
* Or in other brain artery: vertebral, basilar or other intracranial artery (based on CTA, MRA, XRA)
* Or in coronary arteries (past history of acute coronary syndrome, coronary revascularization or positive coronary angiography)

• And
* Statin treatment is indicated, following ANSM guidelines (French drug agency)
* age \>18 years
* rankin score ≤ 4
* patient or a legal representative signs consent
* Patient is affiliated to social security system

• Symptomatic hemorrhagic stroke

Exclusion Criteria

* • Ischemic stroke/TIA du to
* arterial dissection (investigator judgment)

* Uncontrolled hypertension (investigator judgment)
* LDL-C \<100 mg/dL or patients for whom treatment intensification is impossible
* F/U impossible or bad observance anticipated.
* Co-morbid condition that may interfere with the F/U or with the evaluation of primary endpoint
* Participation to another clinical trial

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No